ATE194773T1 - Verfahren zur behandlung von verletzten oder degenerierten photorezeptoren mit einem neurotrophischen faktor aus der glial-zellinie (gdnf) - Google Patents

Verfahren zur behandlung von verletzten oder degenerierten photorezeptoren mit einem neurotrophischen faktor aus der glial-zellinie (gdnf)

Info

Publication number
ATE194773T1
ATE194773T1 AT96941452T AT96941452T ATE194773T1 AT E194773 T1 ATE194773 T1 AT E194773T1 AT 96941452 T AT96941452 T AT 96941452T AT 96941452 T AT96941452 T AT 96941452T AT E194773 T1 ATE194773 T1 AT E194773T1
Authority
AT
Austria
Prior art keywords
treating
retinopathies
gdnf
cell line
neurotrophic factor
Prior art date
Application number
AT96941452T
Other languages
English (en)
Inventor
Jean-Claude Marcel Louis
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE194773T1 publication Critical patent/ATE194773T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Non-Volatile Memory (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96941452T 1995-11-29 1996-11-22 Verfahren zur behandlung von verletzten oder degenerierten photorezeptoren mit einem neurotrophischen faktor aus der glial-zellinie (gdnf) ATE194773T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/564,833 US5641750A (en) 1995-11-29 1995-11-29 Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
PCT/US1996/018806 WO1997019694A1 (en) 1995-11-29 1996-11-22 Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product

Publications (1)

Publication Number Publication Date
ATE194773T1 true ATE194773T1 (de) 2000-08-15

Family

ID=24256084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96941452T ATE194773T1 (de) 1995-11-29 1996-11-22 Verfahren zur behandlung von verletzten oder degenerierten photorezeptoren mit einem neurotrophischen faktor aus der glial-zellinie (gdnf)

Country Status (20)

Country Link
US (2) US5641750A (de)
EP (1) EP0863766B1 (de)
JP (1) JP2000502057A (de)
KR (1) KR19990071540A (de)
CN (1) CN1203532A (de)
AT (1) ATE194773T1 (de)
AU (1) AU698062B2 (de)
BR (1) BR9611750A (de)
CZ (1) CZ154498A3 (de)
DE (1) DE69609422T2 (de)
DK (1) DK0863766T3 (de)
ES (1) ES2149511T3 (de)
GR (1) GR3034393T3 (de)
HU (1) HUP9802374A2 (de)
IL (1) IL124601A0 (de)
MX (1) MX9803993A (de)
NO (1) NO982275L (de)
PT (1) PT863766E (de)
SK (1) SK65998A3 (de)
WO (1) WO1997019694A1 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020064870A1 (en) * 1993-03-03 2002-05-30 Pascale Briand Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases
FR2704556B1 (fr) 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2710846B1 (fr) 1993-10-04 1995-12-22 Rhone Poulenc Rorer Sa Compositions pharmaceutiques et leur utilisation, notamment dans le traitement des maladies neurogénératives.
US8431119B2 (en) * 1993-10-04 2013-04-30 Aventis Pharma S.A. Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
EP0751992B1 (de) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US6878544B2 (en) * 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
CA2265743A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic composition of neurotrophic factor, optic nerve functional disorder-treating agent and method for treating optic nerve functional disorder
EP0937258A2 (de) * 1996-10-29 1999-08-25 Fred Hutchinson Cancer Research Center, Inc. Humane durch zellstress regulierte mhc class i gene
EP0983296A4 (de) * 1997-04-17 2002-11-06 Univ Washington Rezeptoren für tgf beta related neurotrophic factors
US20030121064A1 (en) * 1997-06-11 2003-06-26 Ann Logan CNS neuroregenerative compositions and methods of use
CA2301693A1 (en) * 1997-09-19 1999-04-01 Klaus Unsicker Cytokines having neurotrophic activity
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
FR2784898A1 (fr) * 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
US6906077B1 (en) 1998-12-03 2005-06-14 Alcon Manufacturing, Ltd. Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
IT1305294B1 (it) 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
HK1042052A1 (zh) * 1999-02-08 2002-08-02 Human Genome Sciences, Inc. 内皮血管生长因子-2
US20070071734A1 (en) * 1999-04-06 2007-03-29 Weng Tao ARPE-19 as platform cell line for encapsulated cell-based delivery
US6361771B1 (en) * 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
WO2001074400A1 (en) 2000-04-03 2001-10-11 Santen Pharmaceutical Co., Ltd. Transporters and drug delivery system by using the same
US6864243B1 (en) 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
JP2004505619A (ja) 2000-08-04 2004-02-26 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
PL366000A1 (en) * 2000-08-08 2005-01-24 M.G.V.S.Ltd. Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis
US7109208B2 (en) 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
CN1318093C (zh) * 2001-09-28 2007-05-30 参天制药株式会社 含与聚乙二醇结合的药物的眼组织注射剂
AU2002346611A1 (en) * 2001-12-03 2003-06-17 The Regents Of The University Of California Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
EP1463530A4 (de) * 2001-12-19 2006-09-06 Lijun Wang Adeno-assoziierte virusvermittelte abgabe von gdnf an skelettmuskeln
AU2003209297A1 (en) * 2002-01-18 2003-09-02 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
AU2003249227A1 (en) * 2002-07-12 2004-02-02 University Of Washington Methods and systems for extended in vitro culture of neuronal cells
WO2004028477A2 (en) * 2002-09-29 2004-04-08 Surmodics, Inc. Methods for treatment and/or prevention of retinal disease
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
WO2006071794A2 (en) 2004-12-23 2006-07-06 Ethicon Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US8491883B2 (en) * 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
WO2005001080A2 (en) 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
US7875272B2 (en) * 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US8790637B2 (en) * 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
GB0328021D0 (en) * 2003-12-03 2004-01-07 Inst Of Ophthalmology Method
US20060153815A1 (en) * 2004-12-21 2006-07-13 Agnieszka Seyda Tissue engineering devices for the repair and regeneration of tissue
US20060166361A1 (en) * 2004-12-21 2006-07-27 Agnieszka Seyda Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US20060171930A1 (en) * 2004-12-21 2006-08-03 Agnieszka Seyda Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
WO2006071778A2 (en) 2004-12-23 2006-07-06 Ethicon Incorporated Treatment of parkinson's disease and related disorders using postpartum derived cells
RU2284812C1 (ru) * 2005-02-15 2006-10-10 Уфимский научно-исследовательский институт глазных болезней Способ лечения пролиферативной витреоретинопатии
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
US8409263B2 (en) * 2005-08-05 2013-04-02 Gholam A. Peyman Methods to regulate polarization of excitable cells
US7592330B2 (en) * 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
ITRM20050447A1 (it) * 2005-08-19 2007-02-20 Anabasis S R L Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
WO2007070870A1 (en) * 2005-12-16 2007-06-21 Ethicon, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
WO2007076522A2 (en) * 2005-12-28 2007-07-05 Ethicon, Incorporated Treatment of peripheral vascular disease using postpartum-derived cells
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US20080145405A1 (en) * 2006-12-15 2008-06-19 Kunzler Jay F Drug delivery devices
CA2681850C (en) * 2007-04-20 2013-07-23 Acucela Inc. Styrenyl derivative compounds for treating ophthalmic diseases and disorders
RU2470910C9 (ru) 2007-06-29 2013-05-20 Акьюсела, Инк. Соединения, представляющие собой алкинилфенильные производные, для лечения офтальмических заболеваний и расстройств
JP5323845B2 (ja) * 2007-10-05 2013-10-23 エシコン・インコーポレイテッド ヒト臍帯組織由来細胞を用いた腎組織の修復および再建
CN103553945B (zh) 2007-10-05 2015-01-07 奥克塞拉有限公司 用于治疗疾病的烷氧基化合物
EP2291181B9 (de) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine zur Behandlung von depressionartigen Symptomen
JP6095893B2 (ja) * 2008-12-19 2017-03-15 デピュイ・シンセス・プロダクツ・インコーポレイテッド 傷害後の神経組織の再生および修復
US10179900B2 (en) * 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
CN102387807A (zh) 2008-12-19 2012-03-21 先进科技及再生医学有限责任公司 肺部疾病和病症的治疗
BRPI0923177A2 (pt) * 2008-12-19 2020-08-25 Advanced Technologies And Regenerative Medicine, Llc usos de composições para tratar dor neuropática e espacidade, as referidas composições, e kit
SG174551A1 (en) * 2009-03-26 2011-10-28 Ethicon Inc Human umbilical cord tissue cells as therapy for alzheimer' s disease
AU2012358810B2 (en) 2011-12-23 2018-03-15 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue-derived cells
EP2804605A4 (de) 2012-01-20 2015-07-08 Acucela Inc Substituierte heterocyclische verbindungen zur behandlung von krankheiten
CA2903483A1 (en) 2013-03-12 2014-10-09 Acucela Inc. Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth
WO2017173327A1 (en) 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
WO2018089702A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof
EP4520828A3 (de) 2016-11-15 2025-07-09 The Schepens Eye Research Institute, Inc. Zusammensetzungen und verfahren zur behandlung von aberranter angiogenese
WO2019070917A1 (en) 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
US11739326B2 (en) 2017-11-14 2023-08-29 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
CN113759131B (zh) * 2021-09-28 2024-10-29 嘉兴蔚康科技有限公司 一种靶标蛋白组合在检测视网膜黄斑病变中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3995635A (en) * 1971-09-09 1976-12-07 Alza Corporation Ocular insert
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4217898A (en) * 1978-10-23 1980-08-19 Alza Corporation System with microporous reservoir having surface for diffusional delivery of agent
US4474452A (en) * 1981-05-13 1984-10-02 Pitney Bowes Inc. Safety device for cam yoke used in electrophotocopier reciprocating carriage
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4474752A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4882150A (en) * 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO1990006952A1 (fr) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5221696A (en) * 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
DK0423980T3 (da) * 1989-10-16 2000-10-09 Amgen Inc Stamcellefaktor
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU679167B2 (en) * 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
WO1993015608A1 (en) * 1992-02-14 1993-08-19 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
WO1993021902A1 (en) * 1992-04-24 1993-11-11 Somatix Therapy Corporation Biocompatible, therapeutic, implantable device
AU1443095A (en) * 1993-12-22 1995-07-10 University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product

Also Published As

Publication number Publication date
IL124601A0 (en) 1998-12-06
JP2000502057A (ja) 2000-02-22
EP0863766A1 (de) 1998-09-16
NO982275D0 (no) 1998-05-19
US5736516A (en) 1998-04-07
CN1203532A (zh) 1998-12-30
PT863766E (pt) 2000-11-30
KR19990071540A (ko) 1999-09-27
GR3034393T3 (en) 2000-12-29
CZ154498A3 (cs) 1999-05-12
HUP9802374A2 (hu) 1999-02-01
EP0863766B1 (de) 2000-07-19
BR9611750A (pt) 1999-04-06
MX9803993A (es) 1998-09-30
DK0863766T3 (da) 2000-10-23
AU698062B2 (en) 1998-10-22
ES2149511T3 (es) 2000-11-01
DE69609422T2 (de) 2001-02-15
SK65998A3 (en) 1999-09-10
WO1997019694A1 (en) 1997-06-05
AU1059297A (en) 1997-06-19
NO982275L (no) 1998-07-29
DE69609422D1 (de) 2000-08-24
US5641750A (en) 1997-06-24

Similar Documents

Publication Publication Date Title
ATE194773T1 (de) Verfahren zur behandlung von verletzten oder degenerierten photorezeptoren mit einem neurotrophischen faktor aus der glial-zellinie (gdnf)
ATE194081T1 (de) Verfahren zur behandlung von verletzungen retinaler ganglione mit neurotrophischem faktor aus der glialzellinie (gdnf)
DE69634301D1 (de) Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)
ATE98219T1 (de) Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte.
DE2522484B2 (de) Verfahren zur herstellung eines in waessrigen medien unloeslichen produkts mit enzymatischer aktivitaet
ATE181235T1 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
DE3686108D1 (de) Verwendung von p-chlorophenoxyazetat von n,n-dimethylbiguanid zur behandlung von neuropathien und nervendegeneration.
WO2001009327A3 (en) Method of preventing the injury or death of retinal cells and treating ocular diseases
DE60215649D1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
DE69903612D1 (de) Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten
ATE15897T1 (de) Ausgangsprodukte zur herstellung von cephalosporinen und verfahren zu ihrer herstellung.
BR9915803A (pt) Composição para o tratamento de neuropatia da retina ou cabeça de nervo ótico, e, processo para tratamento de neuropatia da retina ou cabeça de nervo ótico
ATE65778T1 (de) 4-oxo-thiazolidin-2-yliden-acetamid-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel zur bekaempfung von erkrankungen des zentralnervensystems.
EP0330647B1 (de) Verwendung von Chymotrypsin zum Unwirksammachen des Präkallikrein-Aktivators
EP1185683B1 (de) Verfahren zur verzögerung der desaktivierung von glutarylamidase während einer enzymkatalyse
DE2757084A1 (de) Weiche kontaktlinse und deren herstellungsverfahren
EP0238986A3 (de) Verfahren zur Herstellung eines den Blutgerinnungsfaktor VIII in ankonzentrierter Form enthaltenden Präparates
DE398009C (de) Verfahren zur Herstellung eines von anorganischen Salzen freien, hellfarbigen Albumins aus Blutserum
EP0682032A3 (de) Verfahren zur Aufarbeitung von kupferhaltigen Rückständen aus der Organochlorsilansynthese
SU1297845A1 (ru) Способ лечени миопии
DE2113132A1 (de) Verfahren zum Oberflaechenvergueten von biologisch gebildetem Calciumcarbonat wie Perlmutt,Natur- bzw. Zuchtperlen und hiernach hergestellte Gegenstaende
JPH0284554A (ja) 絹の変色防止方法

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification